HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, has announced that the U.S. Food and Drug Administration (FDA) accepted its HeartBeam System into the Total Product Life Cycle Advisory Program (TAP) Pilot. This acceptance follows the receipt of Breakthrough Device Designation earlier this month and marks a significant step toward accelerating the development and patient access of HeartBeam's 3D electrocardiogram (ECG) technology, which is being developed to assess potential heart attacks outside traditional medical settings.
The TAP program provides dedicated FDA advisors, expedited regulatory feedback, and access to healthcare providers, patient advocacy groups, and insurers. This support is designed to streamline the regulatory pathway for innovative medical devices. For HeartBeam, this means closer collaboration with the FDA to refine its study design and regulatory strategy, potentially reducing the time and cost associated with bringing its heart attack assessment technology to market.
The company estimates the heart attack assessment market opportunity at approximately $15 billion within a broader cardiac platform opportunity exceeding $40 billion. This substantial market potential underscores the significance of the FDA's acceptance into TAP. HeartBeam expects to seek FDA alignment on its multicenter pivotal study design in the coming months, with patient enrollment anticipated to begin in the first quarter of 2027. The study is intended to support a future regulatory submission expanding the HeartBeam System's indications to include heart attack assessment.
In addition to TAP, HeartBeam is evaluating eligibility for the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, which is designed to accelerate Medicare access to eligible Breakthrough devices. If successful, this could further enhance the commercial viability of the HeartBeam System by ensuring reimbursement upon approval.
The HeartBeam System is not currently cleared for heart attack detection, and TAP participation does not guarantee future FDA authorization or insurance coverage. However, the company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The HeartBeam System with 12-lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025, and details on the intended use can be found in the company's cleared indications for use.
For investors, the TAP acceptance is a positive signal of the FDA's recognition of HeartBeam's technology and its potential to address a critical unmet need in cardiac care. The latest news and updates relating to BEAT are available in the company's newsroom at https://nnw.fm/BEAT. To view the full press release, visit https://nnw.fm/NdfEK.
NetworkNewsWire, a specialized communications platform, distributed this announcement. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers corporate communications solutions including editorial syndication to 5,000+ outlets and social media distribution. For more information, visit NetworkNewsWire.
